For localized information and support, would you like to switch to your country-specific website for {0}?
STI Testing: Getting to the Point of Care
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
In 2020, there were 211 million new cases of chlamydia and gonorrhea worldwide among adults aged 15 to 49.1 If not treated properly, these infections can cause serious health issues like infertility and ectopic pregnancy. This is particularly problematic in regions with limited access to lab resources, where heavy reliance on symptoms often results in frequent misdiagnosis and inadequate treatment.
Dr. Rebecca Lillis, a renowned expert in infectious diseases, shares her insights on the benefits of molecular Point-of-Care (mPOC) testing for STIs (sexually transmitted infections). This technology brings precise lab-quality diagnostics directly to the point of care, significantly improving the speed and accuracy of STI diagnoses. This ensures appropriate treatment for symptomatic patients, thereby reducing unnecessary treatments, hospital visits, and overall healthcare costs. Dr. Lillis also addresses challenges in traditional clinical workflows without mPOC testing and presents research showing that rapid mPOC testing improves treatment outcomes and optimizes antibiotic use.
Furthermore, Dr. Lillis highlights how mPOC testing enhances satisfaction for both patients and providers. Current mPOC STI tests can deliver results within 30 to 90 minutes,2 allowing diagnosis and treatment to happen in just one visit. This reduces patient waiting time and the need for follow-up communication, which is particularly beneficial where follow-up is difficult.
Please enjoy this informative webinar!
Speakers
References:
- World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 [Internet; cited 2026 Mar 30]. Available from https://www.who.int/publications/i/item/9789240027077
- U.S. Food and Drug Administration. FDA Allows for First Point-of-Care Chlamydia and Gonorrhea Test to be Used in More Near-Patient Care Settings [Internet; cited 2026 Mar 30]. Available from https://www.fda.gov/news-events/press-announcements/fda-allows-first-point-care-chlamydia-and-gonorrhea-test-be-used-more-near-patient-care-settings
https://www.fda.gov/news-events/press-announcements/fda-allows-first-point-care-chlamydia-and-gonorrhea-test-be-used-more-near-patient-care-settings
The views and opinions expressed in this webinar are those of the speakers and do not necessarily reflect the views or positions of Roche or any other sponsors.